On October 20, DKSH is trading 4.03% up at CHF 74.90, following its October 19 announcement that it agreed to acquire NewBridge Pharmaceuticals. - The US$390 million acquisition would establish DKSH Healthcare’s first presence in the Middle East and North Africa. - After completion, the deal is expected to support revenue growth, adjusted EBIT margin and earnings per share. - Subject to regulatory approval, it is expected to close by the end of Q1 2027.